Peregrine Ventures’ Post

*** I looked you up online before but never realized the magnitude of what you are doing*** … You wouldn't believe the countless times I’ve received this feedback. The reality is, healthcare therapeutics is not the typical business for stroytellers Our journey towards a therapy that can completely restore life following Stroke, is like running combo of hurdles race & a marathon run. it’s this past year that made me realize there’s no way around it: stroke touches each and every one of us. Yet, it’s a silent pandemic. It is not discussed, and not addressed, until we or our loved one are faced with its consequences. Website is aimed at everyone, whether you or your loved ones had a stroke, whether you are clinician or a scientist. We aim to share our vision, technology , science and results in most transparent way and engaged with you. BRAIN.Q

🔬 Join Us at RESI Boston for the Diagnostics Panel 🚀 The future of personalized medicine is rapidly evolving, and at RESI Boston, we're diving into the latest advancements in diagnostics. From IVD to genomics and precision medicine, this panel will explore the critical innovations driving the industry forward. 💡 Panel Highlights: Current Trends: Discover where the interest lies in today's diagnostics landscape. Challenges: Learn about the hurdles in navigating a competitive environment and how to overcome them. Investment Strategies: Get insights into successful fundraising and building investor relationships. Regulatory & Developmental Milestones: Understand the key obstacles and how to achieve critical milestones. Meet the Experts: Bruce Cohen - Xeraya Capital (Moderator) Nat Brinn - VC23 Deborah Hemingway, PhD - Ecphora Capital Hannah Mamuszka - 10Edison Capital James Murray - ExSight Ventures Soyoung Park - 1004 Venture Partners Don't miss this chance to gain valuable insights from industry leaders on how to successfully navigate the diagnostics ecosystem. Whether you're a startup looking to fundraise or an established company seeking to stay ahead of the curve, this panel is a must-attend! Register: https://lnkd.in/e7QS-AZi #RESIBoston #Diagnostics #PersonalizedMedicine #Innovation #InvestingInHealthcare

I'm excited to be on the Diagnostics Panel at RESI in Boston on September 25 to talk about the risks, challenges, and path forward for investment in diagnostics. The past couple of years have been brutal for investment in diagnostics, and while our space is starting to recover, there are clear lessons to take from 2020-2022. 1) Investing in tools and kits, and investing in diagnostics, are not the same. Different customers, different markets, different challenges, different path to revenue and returns. 2) Great science, cool technology, concordant clinical validations do not mean there is a diagnostic test that 1) physicians will use to change how they practice or 2) that payors will pay for. If no one uses it, and/or no one pays for it, there is not a product. 3) Experience matters. Teams with no experience bringing clinical diagnostics to the market will have trouble anticipating timelines and capital requirements. 4) Boards can really mess up diagnostic companies. It's great to have big names, distinguished scientists, and blue chip investors on your board, but if you don't have anyone who can give expert guidance from experience, chances of success are lower. Try to find someone that can give clinical and commercial guidance, especially. Come join us! #diagnostics #RESIBoston #precisionmedicine #innovation

One of my favorite annual lists just dropped - The Fierce 15 Biotechs! These 15 companies are breaking barriers and shaping the future of the industry. 🌟 Smaller startup pharma and bio companies have always held a special place in my heart. 💙 Often, firms on the Fierce 15 or similar lists push the boundaries of science and possess the agility to respond swiftly. While not all may succeed, their dedication, creativity, and intelligence are truly inspiring. #Biotech #Innovation #Fierce15 https://lnkd.in/eRXy2Qfj

Amber Therapeutics has developed a solution that scientists previously thought was impossible — a revolutionary implantable system that treats urinary incontinence by targeting the pudendal nerve. For founder Aidan Crawley, this journey into groundbreaking science came after a successful career in finance and software. His true passion: taking on a major unmet healthcare need that could improve millions of lives. “I got exhausted trying to come up with the next trillion-dollar app in crowded markets, wondering if we were inventing problems to solve,” Aidan says. “I wanted to work on a problem that is indisputably real, where the difficulty is in the execution. If you’ve got a cure for a disease that impacts millions of people and you have 55 hurdles to get over, that’s a fun challenge.” Read our full Q&A with Aidan to learn more about his journey founding Amber Therapeutics and why he’s forecasting a bright future for health tech. https://lnkd.in/gH6YYhSE #healthtech #founders #medicine

[ 🗞️ Investing for Impact in BrainTech ] Anne-Sophie Saint-Martin, Partner at Newfund, discusses the advancements BrainTech is making in healthcare in an interview with August Solliv for the Impact Supporters newsletter. The discussion emphasizes BrainTech’s growing significance within the HealthTech industry, exploring current trends, challenges, and the potential societal benefits these technologies offer. Key insights from the interview reveal: 👨  Aging Populations and Chronic Diseases: As the global population ages and chronic diseases proliferate, BrainTech’s role becomes crucial in managing the increasing burden of mental and neurological disorders. 🧠 Diagnostic and Treatment Gaps: Unlike cancer or cardiovascular ailments, neurological conditions lag significantly behind in terms of early diagnosis and effective treatment. 📈 Market Dynamics: Europe rivals the USA in the number and quality of BrainTech startups, yet monetization scales are vastly different, with U.S. markets often commanding significantly higher prices. 🗂️ Regulatory Hurdles: FDA approvals represent a major challenge for BrainTech innovation It also highlights the focus of our #Heka fund, which invests in transformative areas such as AI-enabled diagnostics and digital therapies that aim to enhance life quality. You can read the full interview here : https://lnkd.in/e6QJyJ4h #BrainTech #HealthTech #Newfund #DigitalHealth #ImpactInvesting #Sustainability

Day 1 at the Bloom Burton conference! Great talks from Synaptive Medical, Microbix and Intellijoint Surgical Inc. about their technologies and growth plans. The keynote speech from Eli Casdin did not disappoint either. Eli is the CIO of Casdin Capital, LLC which exclusively invests in the life science sector. Here were some key takeaways he had for investors and industry: - this life science sector is unpredictable and volatile - investors are currently choosing big and safe over small and risky. This will likely change as the margins at the top slim down and investors will lean more into small and risky - the life science sector is important and maybe the most important vertical to invest in - a good management team is the key to a good company - early revenue is a great indicator of success #bloomburton

SonoVascular is honored to have our SonoThrombectomy™ System featured as a “Standout” next-generation venous thrombectomy solution in the March 2024 issue of MedTech Strategist. Our team is excited to disrupt the venous thrombectomy space with our novel pharmaco-mechanical thrombectomy approach, driven by microbubble-mediated mechanical debulking of thrombus. We look forward to partnering with our world class scientific advisory board to bring this important technology forward and positively impact patients’ lives. Full MedTech Strategist article included in this post.   #medtech #healthtech #medtechstartups #medtechinnovator

Advice from those who've been there and done it is always helpful. Starting or scaling a business in Life Science or Tech? Have a look/listen.

Innovation is multi-disciplinary, has multi-dimensional talent and requires multi-lateral engagement I joined #founders, #funders, #investors, #developers, #boardmembers and #talentcultivators at the Cooley LLP and British Patient Capital innovation event. My key take homes were.... 🔍 Nikolai Ahrens shared how #LifeScienceORG brings together talented #CEOs in #biotech, #medtech and #healthtech across Europe to connect and share experiences as #peers and from world class #mentors. 🎨 John Holodnak (Occam Global) spoke with great humour around how we should #experiment, just as how Andy Warhol harnessed technology to push the boundaries of art. 🎭 William Holodnak (Occam Global) made us all think differently about the need for #diversity in #highperforming executive #talent when building a #biotech or #techbio through considering the team as the #visionaries, #producers, #directors and #players in a movie. ⚛ Kamil Tamiola, Ph.D. (Peptone) shared how the most #disruptiveinnovation requires tenacity. We agreed that as #ai disrupts #lifescience, we are only just discovering whether #hallucination in #structuralbiology is wrong, or just an artefact of how we have historically measured molecules. 💡 Richard J. Law (Exscientia) powerfully articulated how #ai in #drugdiscovery is #hypothesis generation using the analogy of #designofexperiment at scale. 🏹 Edith Hessel (Relation) articulated the criticality of staying on target and build #proof-points along the way. ⚡ Alex Pasteur (F-Prime Capital) reinforced how interest and investment is growing in #techbio. 🌡 Danielle Belgrave (GSK) shared the need to follow opportunities for innovation across discovery and #clinical research. Thanks to Emma Johnson and Charlotte Davison (British Patient Capital) and Frances Stocks Allen (Cooley LLP) for hosting the event.